NASDAQ:LPCN - Lipocine Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.39 +0.01 (+0.72 %)
(As of 07/22/2018 10:41 AM ET)
Previous Close$1.39
Today's Range$1.36 - $1.43
52-Week Range$1.03 - $5.33
Volume50,019 shs
Average Volume61,126 shs
Market Capitalization$29.56 million
P/E Ratio-1.32
Dividend YieldN/A
Beta0.42
Lipocine logoLipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics, facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that is currently in Phase II testing; and LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth and has completed an end-of-Phase II meeting with the Food and Drug Administration. Lipocine Inc. is headquartered in Salt Lake City, Utah.

Receive LPCN News and Ratings via Email

Sign-up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LPCN
CUSIPN/A
Phone801-994-7383

Debt

Debt-to-Equity Ratio0.52
Current Ratio5.03
Quick Ratio5.04

Price-To-Earnings

Trailing P/E Ratio-1.32
Forward P/E Ratio-1.58
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.89 per share
Price / Book1.56

Profitability

EPS (Most Recent Fiscal Year)($1.05)
Net Income$-20,980,000.00
Net MarginsN/A
Return on Equity-89.14%
Return on Assets-67.72%

Miscellaneous

Employees14
Outstanding Shares21,260,000
Market Cap$29.56

Lipocine (NASDAQ:LPCN) Frequently Asked Questions

What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

How were Lipocine's earnings last quarter?

Lipocine Inc (NASDAQ:LPCN) announced its quarterly earnings data on Monday, May, 7th. The specialty pharmaceutical company reported ($0.13) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.21) by $0.08. The specialty pharmaceutical company earned $0.43 million during the quarter. View Lipocine's Earnings History.

When is Lipocine's next earnings date?

Lipocine is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Lipocine.

What price target have analysts set for LPCN?

5 Wall Street analysts have issued 1-year target prices for Lipocine's shares. Their predictions range from $2.00 to $38.00. On average, they anticipate Lipocine's stock price to reach $12.80 in the next year. This suggests a possible upside of 820.9% from the stock's current price. View Analyst Ratings for Lipocine.

What is the consensus analysts' recommendation for Lipocine?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lipocine in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Lipocine's key competitors?

Who are Lipocine's key executives?

Lipocine's management team includes the folowing people:
  • Dr. Mahesh V. Patel, Co-Founder, Chairman, Pres & CEO (Age 61)
  • Mr. Morgan R. Brown, Exec. VP, CFO & Corp. Sec. (Age 50)
  • Logan Morse, VP of Sales, Marketing & Operations (Age 48)
  • Mr. Gregory B. Bass, Exec. VP & Chief Commercial Officer (Age 44)
  • Nachiappan Chidambaram, VP of Product Devel. (Age 49)

Has Lipocine been receiving favorable news coverage?

News coverage about LPCN stock has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Lipocine earned a news sentiment score of 0.12 on Accern's scale. They also gave media stories about the specialty pharmaceutical company an impact score of 44.19 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Lipocine?

Shares of LPCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lipocine's stock price today?

One share of LPCN stock can currently be purchased for approximately $1.39.

How big of a company is Lipocine?

Lipocine has a market capitalization of $29.56 million. The specialty pharmaceutical company earns $-20,980,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. Lipocine employs 14 workers across the globe.

How can I contact Lipocine?

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company can be reached via phone at 801-994-7383 or via email at [email protected]


MarketBeat Community Rating for Lipocine (NASDAQ LPCN)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  185 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  291
MarketBeat's community ratings are surveys of what our community members think about Lipocine and other stocks. Vote "Outperform" if you believe LPCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPCN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.